# Optimizing Care for Cryptococcal Antigenemia: Evaluation of Short Course Fluconazole and ART Timing Among CrAg+ Persons With Low Titers

> **NCT07743593** · PHASE3 · NOT_YET_RECRUITING · sponsor: **University of Minnesota** · enrollment: 505 (estimated)

## Conditions studied

- Cryptococcal Antigenemia
- HIV-1-infection
- Cryptococcal Infection
- Cryptococcal Meningitis

## Interventions

- **DRUG:** Immediate ART Initiation
- **DRUG:** Delayed ART Initiation
- **DRUG:** 10-Week Fluconazole
- **DRUG:** 24-Week Fluconazole

## Key facts

- **NCT ID:** NCT07743593
- **Lead sponsor:** University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-01-05
- **Primary completion:** 2031-08-30
- **Final completion:** 2031-08-30
- **Target enrollment:** 505 (ESTIMATED)
- **Last updated:** 2026-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07743593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07743593, "Optimizing Care for Cryptococcal Antigenemia: Evaluation of Short Course Fluconazole and ART Timing Among CrAg+ Persons With Low Titers". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07743593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*